Biologics API MarketSize, Share & Industry Analysis, 2026-2034By Molecule TypeBy Expression SystemBy SourceBy Manufacturing ModeBy Scale of OperationBy Process TypeBy Bioreactor TechnologyBy Therapeutic AreaBy Route of AdministrationBy End User
Full title & scope — all 10 axes with their segments
Biologics API Market Size, Share & Industry Analysis, By Molecule Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell and Gene Therapy, Peptides and Oligonucleotides, Plasma-Derived Products), By Expression System (Mammalian Cells, Microbial, Insect Cells, Plant-Based, Cell-Free), By Source (Innovator Biologics, Biosimilars), By Manufacturing Mode (In-House Manufacturing, Outsourced), By Scale of Operation (Preclinical, Clinical, Commercial), By Process Type (Batch, Fed-Batch, Perfusion and Continuous), By Bioreactor Technology (Single-Use Systems, Stainless Steel Systems), By Therapeutic Area (Oncology, Autoimmune and Inflammatory Diseases, Infectious Diseases, Metabolic Disorders, Neurology, Rare and Genetic Diseases), By Route of Administration (Injectable, Oral, Inhalation, Topical), By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Development and Manufacturing Organizations, Academic and Research Institutes), and Regional Forecast, 2026-2034
Segment definitions and share of revenue by product, animal, end user and region.
Segmentation Analysis
10 axesBy Molecule Type
6- 01Monoclonal Antibodies
- 02Recombinant Proteins
- 03Vaccines
- 04Cell and Gene Therapy
- 05Peptides and Oligonucleotides
- 06Plasma-Derived Products
By Expression System
5- 01Mammalian Cells
- 02Microbial
- 03Insect Cells
- 04Plant-Based
- 05Cell-Free
By Source
2- 01Innovator Biologics
- 02Biosimilars
By Manufacturing Mode
2- 01In-House Manufacturing
- 02Outsourced (CDMO)
By Scale of Operation
3- 01Preclinical
- 02Clinical
- 03Commercial
By Process Type
3- 01Batch
- 02Fed-Batch
- 03Perfusion and Continuous
By Bioreactor Technology
2- 01Single-Use Systems
- 02Stainless Steel Systems
By Therapeutic Area
6- 01Oncology
- 02Autoimmune and Inflammatory Diseases
- 03Infectious Diseases
- 04Metabolic Disorders
- 05Neurology
- 06Rare and Genetic Diseases
By Route of Administration
4- 01Injectable
- 02Oral
- 03Inhalation
- 04Topical
By End User
4- 01Pharmaceutical Companies
- 02Biotechnology Companies
- 03Contract Development and Manufacturing Organizations
- 04Academic and Research Institutes
Segment categories shown for scope reference. See the Summary tab for revenue share by Molecule Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Biologics API Market projected to reach?
USD 138.6 USD Billion by 2034, CAGR 7.8%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Monoclonal Antibodies is the largest line by molecule type, at 46% of revenue in 2025.
06Who are the key companies profiled?
Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation), Thermo Fisher Scientific Inc., Catalent, Inc., AGC Biologics, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Amgen Inc., Celltrion, Inc., Sandoz Group AG, Merck KGaA, Pfizer Inc., Biocon Biologics Ltd., Rentschler Biopharma SE, Polpharma Biologics S.A., Abzena Ltd., Emergent BioSolutions Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc, Resilience (National Resilience, Inc.), Cytovance Biologics, Inc., Wacker Biotech GmbH, Bachem Holding AG. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.